Literature DB >> 20543212

Nephrogenic syndrome of inappropriate antidiuresis.

Elena N Levtchenko1, Leo A H Monnens.   

Abstract

The nephrogenic syndrome of inappropriate antidiuresis (NSIAD) is a rare, recently recognized disorder in water balance affecting not only infants but also adults. A new molecular mechanism responsible for NSIAD has recently been identified: a gain of function of the arginine vasopressin (AVP) receptor type 2 (V2R), causing the constitutive activation of the receptor. Clinical presentation and laboratory findings of NSIAD resemble those of the syndrome of inappropriate secretion of antidiuretic hormone and consist of hyponatraemia, seizures and the lack of urinary dilution; however, the AVP levels in plasma are undetectable or very low. An elucidation of the pathophysiology of this syndrome will provide more insight into the action of AVP. An effective treatment of NSIAD is available. It consists of fluid restriction and administration of oral urea. Reported experience with furosemide treatment in NSIAD is still lacking.

Entities:  

Mesh:

Year:  2010        PMID: 20543212     DOI: 10.1093/ndt/gfq324

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  Clinical management of SIADH.

Authors:  Peter Gross
Journal:  Ther Adv Endocrinol Metab       Date:  2012-04       Impact factor: 3.565

2.  Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis.

Authors:  László S Erdélyi; W Alexander Mann; Deborah J Morris-Rosendahl; Ute Groß; Mato Nagel; Péter Várnai; András Balla; László Hunyady
Journal:  Kidney Int       Date:  2015-07-01       Impact factor: 10.612

Review 3.  Focus on neonatal and infantile onset of nephrogenic syndrome of inappropriate antidiuresis: 12 years later.

Authors:  Flaminia Bardanzellu; Maria Cristina Pintus; Valentina Masile; Vassilios Fanos; Maria Antonietta Marcialis
Journal:  Pediatr Nephrol       Date:  2018-03-15       Impact factor: 3.714

Review 4.  Vasopressin and the regulation of aquaporin-2.

Authors:  Justin L L Wilson; Carlos A Miranda; Mark A Knepper
Journal:  Clin Exp Nephrol       Date:  2013-04-13       Impact factor: 2.801

Review 5.  SIAD: practical recommendations for diagnosis and management.

Authors:  M Cuesta; A Garrahy; C J Thompson
Journal:  J Endocrinol Invest       Date:  2016-04-19       Impact factor: 4.256

6.  A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine.

Authors:  Bianca Berghuis; Caragh Stapleton; Anja C M Sonsma; Janic Hulst; Gerrit-Jan de Haan; Dick Lindhout; Rita Demurtas; Roland Krause; Chantal Depondt; Wolfram S Kunz; Federico Zara; Pasquale Striano; John Craig; Pauls Auce; Anthony G Marson; Hreinn Stefansson; Terence J O'Brien; Michael R Johnson; Graeme J Sills; Stefan Wolking; Holger Lerche; Sanjay M Sisodiya; Josemir W Sander; Gianpiero L Cavalleri; Bobby P C Koeleman; Mark McCormack
Journal:  Epilepsia Open       Date:  2019-01-17

7.  Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion.

Authors:  Eva Perelló-Camacho; Francisco J Pomares-Gómez; Luis López-Penabad; Rosa María Mirete-López; María Rosa Pinedo-Esteban; José Ramón Domínguez-Escribano
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.